# Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab

> **NCT02338245** · PHASE2 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ASLAN001
- **DRUG:** Lapatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02338245
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-29
- **Primary completion:** 2016-05-19
- **Final completion:** 2016-08-25
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338245, "Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02338245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*